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Objective: To describe clinical, laboratory, radiological and progression characteristics of
myelopathy in systemic lupus erythematosus (SLE).
Patients and methods: A retrospective analysis was performed on a cohort of 1193 patients
with SLE (ACR criteria) in order to identify patients with myelopathy (neuropsychiatric ACR).
Disease activity was assessed by the SLE activity index (SLEDAI) on the date of the event and
functional capacity was assessed by the Expanded Disability Status Scale (EDSS) at the last
visit.
Results: We identiﬁed 14 (1.2%) patients with myelopathy. All were women with a mean
age  of 30 ± 11.5 years. Myelopathy occurred at the diagnosis of SLE in four (28%) patients;
and  nine (64%) patients had another type of neuropsychiatric manifestation associated.
Neurological recurrence was observed in one (7%) patient. Disease activity was observed in
2  (14%) patients. Cerebrospinal ﬂuid presented pleocytosis on 7 (53%) patients; antiphos-
pholipid antibodies were positive in 5 (45%). Magnetic resonance imaging (MRI) showed T2
hyperintensity with a predominance of longitudinal involvement in 6 (86%) patients. Most
were  treated with intravenous corticosteroids and cyclophosphamide. No patient had full
recovery and four (36%) had high EDSS scores. Three (21%) patients died from sepsis early
in  the course of their myelopathy, during or after immunosuppressive therapy.
Conclusions: Myelopathy occurred in 14 (1.2%) of the patients in our cohort and this may be
the  ﬁrst manifestation of the disease occurring independently of systemic disease activity.
Although rare, myelopathy shows great morbidity and mortality, can be recurrent and MRIis  critical for diagnosis.© 2016 Published by Elsevier Editora Ltda. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Mielopatia  no  lúpus  eritematoso  sistêmico:  achados  clínicos,
laboratoriais,  radiológicos  e  evolutivos  em  uma  coorte  de  1.193  pacientes
Palavras-chave:
Lúpus eritematoso sistêmico
Mielopatia
Mielite transversa
Ressonância magnética
r  e  s  u  m  o
Objetivo: Descrever características clínicas, laboratoriais, radiológicas e evolutivas de
mielopatia no lúpus eritematoso sistêmico (LES).
Pacientes e métodos: Foi realizada análise retrospectiva de uma coorte de 1193 pacientes com
LES  (critérios ACR), para identiﬁcar os pacientes com mielopatia (ACR neuropsiquiátrico).
A  atividade de doenc¸a foi analisada pelo Índice de Atividade do LES (SLEDAI) na data do
evento e a capacidade funcional pela Escala Expandida do Estado de Incapacidade (EDSS)
na  última consulta.
Resultados: Foram identiﬁcados 14 (1,2%) pacientes com mielopatia. Todas eram mulheres
com  média de idade de 30 anos (DP ± 11,5 anos). A mielopatia ocorreu no diagnóstico do LES
em  quatro (28%) e em nove (64%) havia outro tipo de manifestac¸ão neuropsiquiátrica asso-
ciada. Recorrência do quadro neurológico foi observado em uma (7%) paciente. Atividade
de doenc¸a foi observada em 2 (14%) pacientes. O líquido cefalorraquidiano apresentava
pleocitose em 7 (53%) pacientes anticorpos antifosfolípides eram positivos em 5 (45%). A
ressonância magnética (RM) demonstrou hipersinal em T2 com predomínio do comprome-
timento longitudinal em 6 (86%) pacientes. A maioria foi tratada com corticosteroides e
ciclofosfamida endovenosos. Nenhuma paciente teve completa recuperac¸ão e quatro (36%)
tinham escores altos da EDSS. Óbito foi observado em 3 (21%) durante episódio de mielopatia,
por  septicemia durante ou após terapia imunossupressora.
Conclusões: A mielopatia ocorreu em 14 (1,2%) dos pacientes da nossa coorte e pode ser a
primeira manifestac¸ão da doenc¸a ocorrendo independentemente de atividade sistêmica da
doenc¸a.  Embora rara, é de grande morbimortalidade, pode ser recorrente e a RM é funda-
mental para o diagnóstico.
© 2016 Publicado por Elsevier Editora Ltda. Este é um artigo Open Access sob a licença
de  CC
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europsychiatric manifestations in systemic lupus erythe-
atosus (SLE) have an important impact on the prognosis of
he disease by their frequency and severity.1 Myelopathy is a
anifestation of the central nervous system (CNS) that occurs
nly rarely in SLE, affecting about 1–2% of patients.1–3
In 1999, the American College of Rheumatology (ACR)
stablished the criteria of neuropsychiatric manifestations in
LE, including myelopathy. This possibility should be consid-
red if the patient shows a rapid progression (hours or days) of
ne or more  of the following signs/symptoms: bilateral mus-
le weakness in lower limbs, with or without involvement
pper limbs; a sensory disorder with similar level of motor
mpairment, with or without bowel or bladder involvement.
xpansive injury causing spinal cord compression and cauda
quina injury should be ruled out.4
In 2002, the Transverse Myelitis Consortium Working Group
roposed diagnostic criteria for idiopathic transverse myeli-
is, deﬁned with the clinical manifestations described above,
ssociated with inﬂammation within the spinal cord demon-
trated by cerebrospinal (CSF) pleocytosis or increased IgG
ndex or gadolinium enhancement in magnetic resonance
maging (MRI).5
Myelopathy may present as a transverse myelopathy with
ectional involvement of one level of the spinal cord, or as a
ongitudinal myelopathy in which more  than three segments
re affected, continuously or not.6 BY-NC-ND (http://creativecommons.org/licenses/by-nc-nd/4.0/).
The term myelitis is still used by many authors; how-
ever, myelopathy is more  suitable to characterize spinal cord
changes associated with inﬂammatory diseases such as SLE,
this being the nomenclature recommended by ACR.4
The cause of myelopathy in SLE is not well understood
and the participation of both thrombosis and vasculitis
have been implicated in this process.3 Some authors sug-
gest that there is a relationship between antiphospholipid
antibodies and myelopathy, which would augment the pos-
sibility of thrombosis; but other studies do not conﬁrm this
association.7–10
Although rare, thanks to its importance this condition
was recently included in the new classiﬁcation criteria of the
disease.11 The literature only presents case reports, with the
publication of case series only by a few authors.8,10,12–19
The aim of this study is to describe cases of myelopathy in
SLE, from a cohort of a single university hospital, describing
their clinical picture, laboratory results, imaging ﬁndings on
MRI  of the spinal cord, treatment and outcome.
Patients  and  methods
Medical records of a cohort of 1193 patients with SLE,20 fol-
lowed at the Rheumatology outpatient clinic of the Hospital
das Clínicas, Universidade Estadual de Campinas (UNICAMP)
were analyzed retrospectively.
Patients with myelopathy were identiﬁed by the presence
of acute clinical manifestations suggestive of spinal cord
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injury, and of sensory and motor changes, sphincter dysfunc-
tion, or a combination of these, and changes consistent at
the neurological examination.4,5 Patients with other causes of
myelopathy such as compression, trauma, malignancies and
infections were excluded. Information on demographics, clin-
ical data of SLE disease duration of the myelopathy episode,
adjuvant tests, including imaging studies, auto-antibodies
and cerebrospinal ﬂuid screening were collected. Disease
activity was analyzed by the Systemic Lupus Erythematosus
Disease Activity Index – SLEDAI21 on the day of the event,
when data for application were available, considering disease
activity if SLEDAI ≥6, discrete activity when SLEDAI <6, and
inactivity when SLEDAI = zero.
Information about prescribed treatment and progression of
these patients were also collected. To evaluate the functional
capacity after myelopathy, the Expanded Disability Status
Scale (EDSS) of Kurtzke, applied in the last follow-up visit, was
used.22 This is a method used to quantify disability occurring
during progression and over time.
Ethical  aspects
Authorization of the Research Ethics Committee – FCM UNI-
CAMP was obtained for use of data from patients’ medical
records (Opinion of the Ethics Committee of FCM-UNICAMP:
NO 920/2007).
Results
Fourteen of 1193 (1.2%) SLE patients with myelopathy, all
females and Caucasian, with a mean age at the onset of myelo-
pathy of 30 ± 11.5 years and mean disease duration at the time
of myelopathy of 4 ± 5.2 years (Table 1) were identiﬁed.
Table 1 shows the cumulative clinical manifestations of SLE
until the time of the study. In four of 14 (28%) patients, myelo-
pathy was the initial manifestation. In one (7%) patient, the
diagnosis of SLE was conﬁrmed only two years and 3 months
after the spinal cord manifestation.
The initial symptoms of these 14 patients included uri-
nary retention in 10 (71%), paraplegia in 7 (50%), fever in
6 (42%), paraparesis in 3 (21%) and paresthesia in 2 (14%).
Nine (64%) patients had already had other neuropsychiatric
symptoms before the myelopathy, three (21%) patients with
a clinical picture of psychosis, two (14%) with seizure, one
(7%) with headache, and one (7%) with cerebrovascular dis-
ease (stroke). Two (14%) patients also had optic neuritis (ON).
One (7%) of these patients had severe bilateral optic neuri-
tis many  years after her clinical picture of myelopathy, which
was conﬁrmed by visual evoked potential changes, without
evidence of demyelinating disease on brain MRI, with a neg-
ative result for anti-aquaporin 4 antibody. The other patient
had recurrent neuromyelitis optica (NMO) and was positive
for anti-aquaporin 4 antibody; and SLE was conﬁrmed 3 years
and two  months later, when nephritis, lymphopenia, and pos-
itivity for antinuclear antibody and anti-DNA were noticed.
In these patients we  could not perform other autoantibodies
such as anti-MOG and anti-aquaporin I, but demyelinating
causes were ruled out, and the clinical picture of both of them
was attributed to SLE. 0 1 6;5 6(3):240–251
Only two (14%) patients had nephritis, one of them con-
currently with myelopathy. Six patients had some type of
hematological abnormality during the course of SLE.
Two (14%) patients had disease activity during the episode
of myelopathy, that is, SLEDAI ≥6; in one (7%) patient SLEDAI
was not applied on this occasion, since the diagnosis of SLE
had not been conﬁrmed; in three (21%) patients there was no
data available for the calculation of SLEDAI. In another 8 (57%)
patients SLEDAI was <6, thus with mild disease activity. Only
one (7%) patient had no active disease (Table 1). In these 10
patients in whom it was possible to apply the activity index,
a SLEDAI score was obtained because of fever in 3 (30%), low
complement levels in 9 (90%), anti-DNA positivity in 5 (50%),
psychosis in 1 (10%), nephritis in 1 (10%), thrombocytopenia in
1 (10%) and leukopenia in 1 (10%).
Table 2 shows the additional tests performed during the
episode of myelopathy. All patients had positive tests for
antinuclear antibodies (ANA). Anti-DNA and anti-Sm antibod-
ies were positive in 6 of 13 (46%) patients who were thus
examined, and antiphospholipid antibodies were positive in 5
of 11 (45%) patients submitted to this test. Ten in eleven (90%)
patients who were examined at the time of the myelopathy
had decreased complement levels.
A cerebrospinal ﬂuid (CSF) test was performed in all (100%)
patients with normal results in seven (53%). In six (46%)
patients, pleocytosis with lymphocyte predominance was
noted. The cultures were negative in all 14 (100%) patients.
Full details of CSF of one patient were not available, although
this test had been conducted.
Seven (50%) patients were examined by MRI. The other 7
patients did not perform the test, and in four (28.5%) MRI
was not conducted due to lack of this resource in our Unit
at the time of myelopathy. In these latter patients, myel-
ography was performed in order to rule out other causes,
with normal results in all these women. The other three
(21.5%) patients died without having been able to perform
MRI, because there was no clinical stability for performing this
test.
Upon the clinical episode, all patients underwent spinal
cord MRI in a closed-ﬁeld device. In 6 (86%) cases, patients
had longitudinal lesions with hyperintensity in T2 fast spin-
echo sequences, with extension to 4 or more  vertebral levels
(Fig. 1) and in only one (14%) of these patients the exam-
ination was performed at 3 levels (Table 2). There was
predominantly thoracic involvement in 6 (85%) of these
cases, in 4 (57%) of them with high thoracic levels. A
spinal cord swelling effect was noted in 2 (28%) cases, and
one (14%) of these patients also showed contrast enhance-
ment. As for contrast uptake, only 2 (28%) patients showed
enhancement at the same level of signal exchange in
pre-contrast sequences (Fig. 2). In our cases, it was not
possible to differentiate between white versus gray matter
involvement.
With regard to treatment, eight (57%) patients were treated
with a combination of pulse therapy with methylprednisolone
(MP) followed by intravenous (IV) cyclophosphamide; four
(28%) patients used only MP  pulse therapy; and two  (14%)
received oral corticosteroids at high doses, together with aza-
thioprine. All patients were treated within the ﬁrst hours, or
until 4 weeks after the onset of symptoms.
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Table 1 – SLE: demographic, clinical, and disease activity data of 14 patients with myelopathy.
Patients (n = 14) Race Age (years) Symptoms SLE duration
(years)
Previous NPSLE Cumulative clinical manifestationsa SLEDAI
1 Br 31 Urinary retention/paraparesis 8 Absent Arthritis/photo/leukopenia/APS 4
2 Bl 40 Urinary retention/paraplegia 2 Absent Arthritis/leukopenia/thrombocytopenia 0
3 W 29 Difﬁculty in walking/tactile hypoesthesia 3 Psychosis Arthritis/malar rash/photo 2
4 W 42 Urinary retention/ﬂaccid tetraparesis 0 Seizure Malar rash/photo/oral ulcers 2
5 Br 42 Fever/urinary retention/paraplegia 2 Psychosis Arthritis/malar rash/photo/leucopenia NA
6 W 19 Urinary retention/paresthesia 6 Stroke Arthritis/malar
rash/photo/thrombocytopenia
3
7 Br 20 Fever/urinary retention/paraplegia 9 Absent Arthritis/malar rash/photo/nephritis 17
8 W 18 Paraparesis 1 Absent Arthritis/malar
rash/photo/serositis/lymphopenia
3
9 NA 16 Paresthesia/difﬁculty in walking NAp Optic neuritis Nephritis/lymphopenia b
10 W 9 Fever/urinary retention/paraplegia 1 Optic neuritis Arthritis/malar
rash/photo/pericarditis
3
11 Br 45 Fever/urinary retention/paraplegia 0 Psychosis, stroke Arthritis/discoid/photo/leucopenia 13
12 W 31 Fever/urinary retention/paraplegia 0 Headache Arthritis/alopecia NA
13 Br 41 Paraparesis 16 Seizure and plexopathy Arthritis 4
14 W 30 Fever/urinary retention/paraplegia 13 Absent Malar rash/photo/hemolytic anemia NA
SLE, systemic lupus erythematosus; NPSLE, neuropsychiatric systemic lupus erythematosus; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index; APS, antiphospholipid syndrome; Br,
brown; W, white; Bl, black; photo, photosensitivity; NA, not available; NAp, not applicable.
a Cumulative until the date of the study.
b No diagnosis of SLE available at the time of myelopathy.
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Table 2 – Laboratory tests and imaging ﬁndings on MRI  of 14 SLE patients with myelopathy.
Patients (n = 14) Anti-DNA Complement Anti-phospholipid (LA,
aCL, 2)
Other  antibodies Imaging ﬁndings on spinal cord MRI
(T2 FSE)
CSF
1 + ↓ aCL + LA+ − NA Normal
2 − Normal − Anti-Sm + Longitudinal hyperintensity from C7 to
T9, poorly deﬁned, predominantly in GM,
mild swelling, without contrast
enhancement
Pleocytosis (lymphocytes)
3 − ↓ − − Longitudinal hyperintensity from T1 to
T6, causing tapering without contrast
enhancement
Normal
4 − ↓ LA+ Anti-Sm, anti-Ro and
anti-LA +
Longitudinal hyperintensity from C7 to
T1, focal contrast enhancement in C7
Normal
5 − NA ND − NA Normal
6 + ↓ LA+ − NA Pleocytosis (lymphocytes)
7 + ↓ − Anti-Sm + Longitudinal hyperintensity from C5 to
T2, centromedular region, without
contrast enhancement
Pleocytosis (lymphocytes)
8 − ↓ 2 + − Longitudinal hyperintensity from T1 to
T12 and lumbar area, centromedular
region without contrast enhancement
Pleocytosis (lymphocytes)
9 NA ↓ aCL+ LA+ Anti-AQP4 IgG+ Hyperintensity in the bulb, cerebellar
peduncle and spinal cord through C5,
affects WM and GM, w/o swelling, w/o
contrast enhancement
NA
10 − ↓ − Anti-Sm+ NA Pleocytosis
11 + ↓ ND Anti-Sm+ NA Pleocytosis (lymphocytes)
12 − NA ND − NA Pleocytosis (lymphocytes)
13 + ↓ − Anti-Sm+ and anti Ro + Longitudinal hyperintensity from T11 to
L1 with discrete swelling effect, with focal
contrast enhancement
Normal
14 + NA − − NA Normal
a 6/13 (45%) 10/11 (90%) 5/11 (45%) Anti-Sm 6/13 (46%) 7/7 (100%) 7/13(53%)
SLE, systemic lupus erythematosus; CSF, cerebrospinal ﬂuid; NA, not available; ND, not done; aCL, anticardiolipin antibody; LA lupus anticoagulant; 2, anti-beta 2 glycoprotein I antibody, anti-AQP4
IgG, anti-aquaporin 4; WM, white matter; GM, gray matter; MRI, magnetic resonance imaging, T2 FSE, T2 fast spin-echo sequence
a Ratio between number of changes and tests performed.
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Fig. 1 – Sagittal T2-weighted images showing hyperintensity in spinal cord, extending from the bulb to C3 in the ﬁrst
episode (A) and hyperintensity and increased spinal cord volume extending to C5 in the second episode, seven months
after the ﬁrst one (B).
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Table 3 – Treatment, monitoring and progression of 14
patients with SLE and myelopathy.
Patients Treatment Follow-up EDSS
1 IV MP and IV CYC 6 years 5.5
2 IV MP and IV CYC 14 years 3
3 CS and AZA 15 years 6
4 IV MP and IV CYC 22 years 7.5
5 IV MP 3 years 6
6 IV MP and IV CYC 2 months Death
7 IV MP E IV CYC 4 months 3.5
8 IV MP and IV CYC 12 months 6
9 IV MP, IV CYC, IVIG
and MMF
3  years 3
10 IV MP 24 years 8
11 IV MP 2 months Death
12 CS and AZA 1 year 8
13 IV MP and IV CYC 2 years 8
14 IV MP 8 years Death
SLE, systemic lupus erythematosus; EDSS, Expanded Disability
Status Scale; IV MP, intravenous methylprednisolone; IV CYC, intra-
venous cyclophosphamide; AZA, azathioprine; IVIG, intravenousUpon the application of EDSS after a mean follow-up of
1.5 ± 10.4 years, it was observed that all 11 (78%) patients in
hich it was possible to apply this scale had some degree of
isability, whose score ranged from 3 to 8, i.e. from patients
ble to walk but with some degree of disability, to patients
ith neurogenic bladder requiring wheelchair use. No patient
btained a full recovery.
Three (21%) deaths occurred during the myelopathy man-
festation, caused by a widespread infection that occurred
uring or shortly after the immunosuppressive therapy pre-
cribed for treatment of myelopathy in all three cases.
Table 3 lists treatment, monitoring and progression data.
Table 4 shows the relevant series of cases of myelopathy in
LE which have been published in English language, includ-
ng the present series, with information on MRI ﬁndings.
welve case series are presented, with results showing 4–22
atients and their demographic, respective clinical and labo-
atory characteristics and MRI, treatment and outcome data.
isease activity, recurrence of episodes and the presence of
ther neuropsychiatric symptoms, in addition to the occur-
ence of myelopathy as the ﬁrst manifestation of the disease,
re also highlighted in this table, whenever mentioned by their
uthors.
immunoglobulin; CS, oral corticosteroids; MMF, mycophenolate
mofetil.
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Table 4 – Case series of myelopathy in SLE.
Case series n Age at diagnosis of
myelopathy (years)
Gender Race SLE duration Myelopathy as the
ﬁrst manifestation
(n)
Active SLE Previous NPSLE
Salmaggi et al.12 5 18–46 F (5) NA 2–5 yearsa 2 0 Absent
Provenzale et al.13 4 33–47 F (4) NA NA 1 NA Absent
Harisdangkul et al.14 7 16–52 F (7) NA 3 months to 4 years 4 2 Absent
Kovacs10 14 23–77 F (12) M (2) NA 0–21 years 6 NA D(2)/ON(3)/OS(1)
Telles-Zenteno15 6 23–37 F (6) NA 7 months-16 years 0 3 NA
D’Cruz8 15 21–68 F (15) NA 0 yearsa 15 15 Absent
Lu23 14 15–45 F (12) M (2) A(14) 2 months to 20 years 1 14 ON(3)/ICH(1)
E(1)/OS(1)/HL(1)
Birnbaun16 22 15.5–48.1 (GM) and
16.6–70.5 (WM)
F  (20) M (2) AA(8)/W(9)/other
(5)
5.4–6.5 years 6 11 (GM) and 6
(WM)
ON(6)
Espinosa17 22 12–53 F (17) M (5) NA 0–17 years 5 NA CHO(3)/CE(1)/AM(1)
Schultz18 15 22–78 F (14) M (1) AA(8)/W(7) NA 15 NA ON (2)
Saison19 20 22.9–67.3 F (17) M (3) W
(12)/AA(2)/A(3)/NA(3)
0–36  yearsa 8 20 ON(4)/SE(1)
Costallat et al. (2015) 14 9–42 F (14) W(7)/AA(2)/Br(5) 0–16 yearsa 4 8 ON(2)/SE(2)/OS
(3)c/CVA
(1)/HE(1)/PLE (1)b
Complement↓  (%) APL+ (%) CSF ﬁndings Spinal cord MRI (T2 FSE) Treatment Recurrence (%) Progression
40 20 Oligoclonal
bands (1)
Longitudinal
hypersignal (2)/N
(3)
IV  MP (4)/1 CS(1) 60 CR(3)/PR(2)
NA NA NA Hypersignal (4) IV MP(4)/IV CYC
(2)
75  NA
NA NA NA Longitudinal
hypersig-
nal(3)/ND(4)
IV  MP(4)/CS(3) 43 CR(2)/ND(2)/DEATH(4)
50 54 NA (8)/N
(2)/↑protein (4)
Changed (9)/N (5) IV CYC (9)/P(4) NA CR (3)/PR(2)/UR(9)
50 66 ↑protein (2) Longitudinal
hypersignal(6)
IV  MP(6)/IV CYC
(5)
50  5 w/oR (5)/PR(1)
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Table 4 – (Continued)
Complement↓  (%) APL+ (%) CSF ﬁndings Spinal cord MRI (T2 FSE) Treatment Recurrence (%) Progression
NA 73  Pleocytosis (2)/N
(13)
Changed (11)/N
(2)/ND(1)
IV MP(7)/CS
(6)/AZA (6)
6  CR(6)/PR(9)
28 11 Pleocytosis (6) Longitudinal
hypersignal(6)
focal(5)/N(1)/ND(2)
CS(14)/IV CYC
(2)/P(1)
7  R(4)
NA 54 Pleocytosis (GM) Longitudinal
hypersignal 92%
(GM) and 74%
(WM)
GM group, more
aggressive
therapy
9  (GM) and
73(WM)
GM  group, more disability
(mean of EDSS > in GM
group)
74 50 Predominance of
pleocytosis
Longitudinal
hypersignal (22)
IV  MP(22)/IV CYC
(13)/IV
IG(4)/P(4)/RTX (2)
18  CR(3)/PR(13)/w/oR(6)
87 11 ↑protein Predominance of
focal lesion
IV  MP(14)/IV CYC
(2)/P(1)
NA  NA
87 45 Pleocytosis (5) Longitudinal
hypersignal(9)/N
(3)
IV  MP (18)/IV
CYC (11)/IV
IG(2)/P(3)/RTX(3)
50  CR(5)/PR(12)/w/oR(1)/O(1)
90 45 Pleocytosis (7)/N
(6)
Longitudinal
hypersignal(7)
IV  MP(12)/CS
(2)/IV CYC
(10)/AZA(1)
7  CR(0)/PR(7)/w/oR(4)/DEATH(3)
SLE, systemic lupus erythematosus; NPSLE, neuropsychiatric systemic lupus erythematosus; APL, antiphospholipid antibody; CSF, cerebrospinal ﬂuid; FSE T2, T2 fast spin-echo sequence; F, female; M,
male; AA, African American; Br, brown,; A, Asian; W, white; NA, not available; ND, not done; N, Normal; GM, gray matter; WM, white matter; CHO, chorea; CE, cerebritis; HE, headache; SE, seizure; AM,
aseptic meningitis; ICH, intracranial hemorrhage; HL, hearing loss; PS psychosis; PLE, plexopathy; E, epilepsy; ON, optic neuritis; D, depression; CVA, stroke; IV MP, intravenous methylprednisolone;
IV CYC, intravenous cyclophosphamide; AZA, azathioprine; IVIG, intravenous immunoglobulin; CS, corticosteroids; P, plasmapheresis; RTX, Rituximab; CR, complete remission; PR, partial remission;
R, remission; w/oR without remission.
a With cases of myelopathy preceding SLE.
b With seizure.
c With stroke.
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Fig. 2 – Sagittal T2-weighted image, showing hyperintensity and mild enlargement of spinal cord volume, extending from
T11 to the medullary cone. B, T1-weighted sagittal image after contrast injection, with foci of medullary enhancement
(arrow) extending from T11 to L1. C, Axial T2-weighted images demonstrating the spinal cord with a normal signal
obtained at the T10 level (1) and spinal cord with hyperintensity obtained at the level of T12 (2).Discussion
Myelopathy is one of the most rare neuropsychiatric mani-
festations in SLE, affecting about 1–2% of patients, but this
condition is very relevant, thanks to its high morbidity and
mortality and has been included in the new SLE criteria.11
Our 14 patients represented 1.2% of the cohort of 1193
patients with SLE, a percentage similar to that observed in
previous studies.1,2
All patients were female, as noted by all authors and
in line with the gender proﬁle of this disease.8,10,12–19,23
Myelopathy can affect individuals of all ages; our patients
had a mean age of 30 years – a lower mean than that
observed by other authors,8,10,12,13,15,17–19,23 and similar to
those described in two series.14,15 As for the race, there
is no reference to a higher prevalence of this mani-
festation in any ethnic group, and many  authors have
not highlighted this demographic characteristic. However,
Schutz et al., in a comparison of myelopathy in SLE ver-
sus idiopathic myelopathy, comment the highest frequency
of African–American women with SLE, but this fact can beattributed to the prevalence of the disease itself in that
area.18
Initial symptoms are nonspeciﬁc and may include a short
viral prodrome: fever, photophobia, nausea, vomiting, dizzi-
ness and nuchal pain. Subsequently, sensory and motor
changes and sphincter dysfunction can occur, and its onset
can take hours, days or even weeks. Our myelopathy patients
presented with urinary retention and fever, which was ini-
tially confused, in some cases, with urinary tract infection.
The spinal cord injury clues were paresthesia, walking difﬁcul-
ties, paraplegia and sphincter dysfunction, with sudden onset
within hours or days.
In a systematic review of 22 cases reported in the litera-
ture by Espinosa et al., the authors observed in 23% of cases
a prodromal picture of fever, cough, ﬂu and constitutional
symptoms a few days before the onset of myelopathy,17 which
was observed also by Harisdangkul et al.11 The presence of
fever and urinary retention was associated with an irreversible
16paraplegia, according to Birnbaum et al.
Myelopathy may be the initial manifestation of SLE, as hap-
pened with four of our patients; and this fact was noted by all
authors listed in Table 4, with the exception of Tellez-Zenteno
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t al.15 Some authors consider that when myelopathy occur
n SLE, this can be an initial manifestation in up to 39% of
atients within the ﬁrst ﬁve years.10 By analyzing the series
f reported cases (Table 4), and taking into account the time
oint where the myelopathy may arise during the progression
f SLE, we  can observe the occurrence of a variable percent-
ge for the duration of SLE, and there are cases in which
he patient already had SLE for 36 years before the onset of
yelopathy.19 It is also possible that myelopathy arises before
LE; this happened in one case in our series, in which the
atient presented with spinal cord manifestations 2 years and
 months before her diagnosis of SLE. All 15 cases described
y D’Cruz et al.8 were affected by myelopathy as the initial
anifestation of SLE, and only 4 (26%) met  ACR criteria for
LE at the onset of myelopathy. Of the ﬁve cases of Salmaggi
t al.,12 in two patients myelopathy preceded SLE, and the
ame occurred with 4 (20%) of 20 cases of a French multicen-
er study. In this French study, two cases had myelopathy for
ore  than 10 years before the establishment of a diagnosis of
LE.19 Salmaggi et al.12 concluded that in women with myelo-
athy of unknown etiology, exhaustive clinical and laboratory
ssessments are critical to try to deﬁne SLE.
Although myelopathy in SLE can be recurrent,6,10 in our
eries 13 (93%) patients had a single episode of this condition;
nd only one (7%) patient experienced recurrence. Recurrence
as observed in many  case series, in some of them with high
requency (50–75%) as emphasized in Table 4.8,10,12–19,23 This
igniﬁcant possibility of recurrence imposes the need for the
mplementation of a maintenance immunosuppressive treat-
ent for these patients, in an attempt to prevent further
rises.
Other neuropsychiatric manifestations have been corre-
ated to the presence of myelopathy in SLE10; in our series such
vents occurred in nine (64%) patients. In most cases, neu-
opsychiatric involvement was an integral part of the clinical
istory of the disease, but without a simultaneous occurrence,
ith the exception of one of the patients who had major
anifestation of psychosis concomitantly with spinal cord
ymptoms, and this patient died after immunosuppressive
herapy. Two (14%) patients had optic neuritis. Optic neuri-
is is a neuropsychiatric manifestation often associated with
yelopathy, also known as Devic disease or neuromyelitis
ptica (NMO), and this condition was reported in some of the
eries of cases presented in Table 4. For some authors, the
ssociation with optic neuritis may be present in 21–48% of
ases of myelitis in SLE.10,16,23 Neuromyelitis optica recurrence
as been described in patients positive for anti-aquaporin-
 antibody (anti-AQP4 IgG).24 One of our patients showed
MO associated with positivity for anti-aquaporin 4 antibody,
eing the only case with a recurrent picture of myelopathy.
nother patient with NMO  developed bilateral optic neuri-
is many  years after myelitis, which was conﬁrmed by visual
voked potential test, although anti aquaporin-4 antibody was
egative, which can occur in NMO  cases. In both cases, the
ossibility of demyelinating disease was ruled out, and these
anifestations have been attributed to SLE.
The occurrence of myelopathy may be associated with dis-ase activity. In our series, two patients had active disease (one
ith nephritis and the other with psychosis) and one patient
howed inactive disease; the remaining cases exhibited mild 6;5 6(3):240–251 249
disease activity. Some patients had no clinical and laboratory
data to allow calculation of this index; and SLEDAI was not
applied in one patient because at the time of emergence of
myelopathy the diagnosis of SLE had not yet been conﬁrmed.
Some authors highlight the fact that in one third of cases
myelopathy can occur in a scenario of inactive disease.25 That
is important, because in the face of a relevant clinical picture,
one should always consider myelopathy, regardless of SLE
activity. As for the other authors of the case series presented
in Table 4, not everyone recorded data on disease activity.
With respect to other tests, complement was reduced in
10 (90%) patients of our cases, in some cases accompanied by
other laboratory changes, and in three cases this was the only
punctuation on SLEDAI score.
Antiphospholipid antibodies have been associated with
myelopathy in SLE7,10; in our series, we found these antibod-
ies in 5 (45%) of cases, just as observed by Saison et al.17 But
only one (7%) of our patients fulﬁlled the antiphospholipid
syndrome (APS) criteria. Other authors have found variable
percentages, between 11% and 73% of cases, as shown in
Table 4. According to Birnbaum et al.,16 antiphospholipid anti-
bodies can be important in the pathogenesis of neuromyelitis
optica. In an extensive systematic review by  Katsiari et al.
on the occurrence of these antibodies in cases of transverse
myelitis and the use of anticoagulation in the presence of
myelopathy, these authors concluded that, while antiphos-
pholipid antibodies may have a role in the pathogenesis of
myelopathy, the mere  presence of these antibodies is not suf-
ﬁcient to indicate the anticoagulation therapy.26
The ﬁndings of the cerebrospinal ﬂuid analysis are non-
speciﬁc. Some authors found increased cellularity and also
proteinorrhachia,18,23 but often the CSF is normal in patients
with myelopathy.7,10,27 In our series, CSF was collected in all
(100%) patients, and the most frequent change was pleocytosis
(53%), with lymphocyte predominance.
Magnetic resonance imaging is the most sensitive imag-
ing tool in the evaluation of spinal cord injuries, including in
myelopathy associated with SLE. The examination protocol for
MRI  images should cover the level corresponding to neurologi-
cal damage observed on clinical examination, but it is strongly
recommended to study the entire cord. The imaging ﬁndings
may vary, with an emphasis on the T2 hyperintense signal on
spinal cord, the effect of swelling in cases of spinal cord edema,
and also the contrast uptake. Among these ﬁndings, the most
common is the signal change, as was also observed in our
study. We  must bear in mind that in some cases, MRI  may be
normal, especially in the early stages.8,10,12 In cases where the
MRI  imaging with contrast is normal, it is recommended that
the test be repeated 2–7 days after the initial manifestation.5
It is important to note that CT should not be used for
diagnosis of myelopathy because of its low sensitivity. This
technology should be used in cases where the MRI  is unavail-
able, and only to exclude compressive causes of the spinal
cord.5
The thoracic region is the most frequently affected
part, which also occurred in our patients.10,23 This may be
attributed to the type of blood supply that nourishes the
region, with emphasis for the branches of the longitudinal
arteries that are less large in the thoracic region when com-
pared to the cervical or lumbar region; this implies limitation
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in the vascular supply, as concluded by Kovacs et al.10 In
recent years, with the improvement in the quality of images
and equipment, an increase in the identiﬁcation of longitu-
dinal spinal cord injuries was noted in cases of myelopathy
in SLE examined by MRI  – a fact also observed in most of our
patients.15,18
Birnbaum et al. compared patients with lesions in
spinal cord white matter (spasticity and hyperreﬂexia) versus
patients with lesions in the gray matter (ﬂaccidity and hypore-
ﬂexia). These authors concluded that the lesions in the gray
matter are associated with irreversible paraplegia and greater
disease activity.16 We  could not make this distinction in our
patients.
While being very important for the diagnosis of these
patients, MRI  does not seem to have much use for their follow-
up, because there is no clinical correlation after treatment in
the initial stages.18 As for the prognosis, there seems to be a
worse prognosis in patients with changes in MRI  in the begin-
ning of the process, when compared to patients with normal
MRI,10 especially in those cases with presence of extensive
lesions.15
The treatment of myelopathy should be instituted imme-
diately after the diagnosis, as this manifestation has a poor
prognosis, with high morbidity in up to 50% of cases10,23 and
with high mortality. Delayed institution of an appropriate
treatment was the unfavorable outcome factor noted by all
authors selected. The combination of intravenous pulses of
methylprednisolone and cyclophosphamide is considered the
treatment of choice for such patients.6,27 According to Saison
et al.,19 the use of hydroxychloroquine decreased the neu-
rological ﬂares in cases of myelopathy in SLE, although this
ﬁnding was not statistically signiﬁcant. In some cases it is nec-
essary to use intravenous immunoglobulin, plasmapheresis
and rituximab,28 especially in unresponsive or recurrent cases;
but the response vary. Twelve (85%) of our patients received
pulse MP  and 10 (71%) received IV cyclophosphamide within
one month of the onset of symptoms. Our unique case of
recurrence was treated, along the disease progression, with
IV immunoglobulin and mycophenolate mofetil (MMF). None
of our patients achieved full recovery. The evaluation of these
patients by EDSS resulted in scores of 7.5–8 in four of them,
that is, patients with walking difﬁculties and requiring the
use of a wheelchair, besides a neurogenic bladder. All four
(28%) patients used MP  pulse at high doses, and two (14%)
of them were also medicated with IV cyclophosphamide; but
even then the outcome was not favorable, perhaps because
not all of them have used both medications within two weeks
after the onset of the manifestation. In our group, three (21%)
deaths occurred, all caused by an infection during or shortly
after immunosuppressive therapy for treatment of myelo-
pathy. This reinforces the seriousness of this manifestation.
The prognostic factors of myelopathy are not fully known,
but sphincter dysfunction,16,23 MRI  changes,10,16 involvement
of gray matter (ﬂaccidity and hyporeﬂexia),16 and initial sever-
ity with paraplegia19 are cited as poor prognostic factors.
Muscle strength ≥grade 3 at the time of hospitalization and
an aggressive therapy instituted no later than two weeks after
the episode of myelopathy are better prognostic factors.23 In
summary, myelopathy in SLE is very rare, but also very seri-
ous. It occurred in 14 (1.2%) of our patients. Myelopathy may
1 0 1 6;5 6(3):240–251
be the ﬁrst manifestation of the disease, can occur after many
years of an installed SLE, or may even precede the disease.
Although rare, myelopathy has high morbidity and mortality
and may be present, regardless of disease activity. Moreover,
it can be recurrent and therefore it is recommended a mainte-
nance immunosuppressive therapy so that new episodes are
prevented. MRI is essential for diagnosis, but this examination
may be normal in very early stages.
Funding
Capes (Master’s scholarship) and CNPq (302205/2012-8,
466715/2014-5).
Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. West SG. Neuropsychiatric lupus. Rheum Dis Clin N Am.
1994;20:129–58.
2. Theodoridou A, Settas L. Demyelination in rheumatic
diseases. J Neurol Neurosurg Psychiatry. 2006;77:290–5.
3. Allen IV, Millar JH, Kirk J, Shillington RK. Systemic lupus
erythematosus clinically resembling multiple sclerosis and
with unusual pathological and ultrastructural features. J
Neurol Neurosurg Psychiatry. 1979;42:392–401.
4. The American College of Rheumatology nomenclature and
case deﬁnitions for neuropsychiatric lupus syndromes.
Arthritis Rheum. 1999;42:599–608.
5. Group TMCW. Proposed diagnostic criteria and nosology of
acute transverse myelitis. Neurology. 2002;59:499–505.
6. Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S,
Bruce IN, et al. EULAR recommendations for the management
of systemic lupus erythematosus with neuropsychiatric
manifestations: report of a task force of the EULAR standing
committee for clinical affairs. Ann Rheum Dis.
2010;69:2074–82.
7. Lavalle C, Pizarro S, Drenkard C, Sánchez-Guerrero J,
Alarcón-Segovia D. Transverse myelitis: a manifestation of
systemic lupus erythematosus strongly associated with
antiphospholipid antibodies. J Rheumatol. 1990;17:34–7.
8. D’Cruz DP, Mellor-Pita S, Joven B, Sanna G, Allanson J, Taylor J,
et  al. Transverse myelitis as the ﬁrst manifestation of
systemic lupus erythematosus or lupus-like disease: good
functional outcome and relevance of antiphospholipid
antibodies. J Rheumatol. 2004;31:280–5.
9. Mok CC, Lau CS, Chan EY, Wong RW. Acute transverse
myelopathy in systemic lupus erythematosus: clinical
presentation, treatment, and outcome. J Rheumatol.
1998;25:467–73.
0. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse
myelopathy in systemic lupus erythematosus: an analysis of
14  cases and review of the literature. Ann Rheum Dis.
2000;59:120–4.
1. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR,
et al. Derivation and validation of the Systemic Lupus
International Collaborating Clinics classiﬁcation criteria for2012;64:2677–86.
2. Salmaggi A, Lamperti E, Eoli M, Venegoni E, Bruzzone MG,
Riccio G, et al. Spinal cord involvement and systemic lupus
 . 2 0 1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2r e v b r a s r e u m a t o l
erythematosus: clinical and magnetic resonance ﬁndings in 5
patients. Clin Exp Rheumatol. 1994;12:389–94.
3. Provenzale JM, Barboriak DP, Gaensler EH, Robertson RL,
Mercer B. Lupus-related myelitis: serial MR ﬁndings. AJNR Am
J  Neuroradiol. 1994;15:1911–7.
4. Harisdangkul V, Doorenbos D, Subramony SH. Lupus
transverse myelopathy: better outcome with early
recognition and aggressive high-dose intravenous
corticosteroid pulse treatment. J Neurol. 1995;242:
326–31.
5. Téllez-Zenteno JF, Remes-Troche JM, Negrete-Pulido RO,
Dávila-Maldonado L. Longitudinal myelitis associated with
systemic lupus erythematosus: clinical features and magnetic
resonance imaging of six cases. Lupus. 2001;10:851–6.
6. Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct
subtypes of myelitis in systemic lupus erythematosus.
Arthritis Rheum. 2009;60:3378–87.
7. Espinosa G, Mendizábal A, Mínguez S, Ramo-Tello C,
Capellades J, Olivé A, et al. Transverse myelitis affecting more
than 4 spinal segments associated with systemic lupus
erythematosus: clinical, immunological, and radiological
characteristics of 22 patients. Semin Arthritis Rheum.
2010;39:246–56.
8. Schulz SW, Shenin M, Mehta A, Kebede A, Fluerant M, Derk
CT. Initial presentation of acute transverse myelitis in
systemic lupus erythematosus: demographics, diagnosis,
management and comparison to idiopathic cases. Rheumatol
Int.  2012;32:2623–7.
9. Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J,
Marignier R, Cacoub P, et al. Systemic lupus
erythematosus-associated acute transverse myelitis:
manifestations, treatments, outcomes, and prognostic factors
in 20 patients. Lupus. 2015;24:74–81. 6;5 6(3):240–251 251
0. Hochberg MC. Updating the American College of
Rheumatology revised criteria for the classiﬁcation of
systemic lupus erythematosus. Arthritis Rheum.
1997;40:1725.
1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH.
Derivation of the SLEDAI. A disease activity index for lupus
patients. The Committee on Prognosis Studies in SLE.
Arthritis Rheum. 1992;35:630–40.
2. Kurtzke JF. Rating neurologic impairment in multiple
sclerosis: an expanded disability status scale (EDSS).
Neurology. 1983;33:1444–52.
3. Lu X, Gu Y, Wang Y, Chen S, Ye S. Prognostic factors of lupus
myelopathy. Lupus. 2008;17:323–8.
4. Drori T, Chapman J. Diagnosis and classiﬁcation of
neuromyelitis optica (Devic’s syndrome). Autoimmun Rev.
2014;13:531–3.
5. Li XY, Xiao P, Xiao HB, Zhang LJ, Pai P, Chu P, et al. Myelitis in
systemic lupus erythematosus frequently manifests as
longitudinal and sometimes occurs at low disease activity.
Lupus. 2014;23:1178–86.
6. Katsiari CG, Giavri I, Mitsikostas DD, Yiannopoulou KG,
Sﬁkakis PP. Acute transverse myelitis and antiphospholipid
antibodies in lupus. No evidence for anticoagulation. Eur J
Neurol. 2011;18:556–63.
7. Barile L, Lavalle C. Transverse myelitis in systemic lupus
erythematosus – the effect of IV pulse methylprednisolone
and cyclophosphamide. J Rheumatol. 1992;19:370–2.
8. Scott TF, Frohman EM, De Seze J, Gronseth GS, Weinshenker
BG. Neurology TaTASoAAo. Evidence-based guideline: clinical
evaluation and treatment of transverse myelitis: report of the
Therapeutics and Technology Assessment Subcommittee of
the  American Academy of Neurology. Neurology.
2011;77:2128–34.
